About Cresset
Cresset is a company based in Cambridge (United Kingdom) founded in 2002. Cresset has raised $297.86 thousand across 8 funding rounds from investors including Gov.uk, European Union and Scottish Equity Partners. The company has 46 employees as of March 31, 2022. Cresset offers products and services including Flare, Spark, Blaze, and Torx DMTA. Cresset operates in a competitive market with competitors including Aqemia, NTxBio, Applied BioMath, Nimble Therapeutics and Enveda, among others.
- Headquarter Cambridge, United Kingdom
- Employees 46 as on 31 Mar, 2022
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Cresset Biomolecular Discovery Limited
- Date of Incorporation 31 Jan, 2001
- Jurisdiction LITLINGTON, CAMBRIDGESHIRE
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$297.86 K (USD)
in 8 rounds
-
Latest Funding Round
$297.86 K (USD), Seed
Sep 12, 2022
-
Investors
Gov.uk
& 2 more
-
Employee Count
46
as on Mar 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Cresset
Cresset offers a comprehensive portfolio of products and services, including Flare, Spark, Blaze, and Torx DMTA.
Ligand-based and structure-based tool for agile drug discovery.
Generates innovative ideas for molecular design projects.
Increases hit rates in ligand-based virtual screening.
Manages molecule design and synthesis workflows.
People of Cresset
Unlock access to complete
Unlock access to complete
Funding Insights of Cresset
Cresset has successfully raised a total of $297.86K across 8 strategic funding rounds. The most recent funding activity was a Seed round of $297.86 thousand completed in September 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 8
- Last Round Seed — $297,860
- First Round First Round
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2022 | Amount | Seed - Cresset | Valuation |
investors |
|
| Jan, 2021 | Amount | Grant - Cresset | Valuation |
investors |
|
| Sep, 2020 | Amount | Seed - Cresset | Valuation |
investors |
|
Investors in Cresset
Cresset has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Gov.uk, European Union and Scottish Equity Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on tech companies
|
Founded Year | Domain | Location | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Founded Year | Domain | Location | |
|
Online government services and information are provided to users.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Cresset
Financial Statements - Cresset
Cresset Comparisons
Competitors of Cresset
Cresset operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aqemia, NTxBio, Applied BioMath, Nimble Therapeutics and Enveda, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutic molecules are discovered through AI and quantum physics integration.
|
|
| domain | founded_year | HQ Location |
Provider of bio informatics platform to develops biologics and therapeutics
|
|
| domain | founded_year | HQ Location |
Systems biology and pharmacology modeling services to aid drug discovery and development
|
|
| domain | founded_year | HQ Location |
Combinatorial chemistry services for peptide-based drug discovery are provided.
|
|
| domain | founded_year | HQ Location |
Provider of AI-based platform to decipher the chemistry of nature and develop new medicines
|
|
| domain | founded_year | HQ Location |
Precision medicines for immune-mediated inflammatory diseases are developed.
|
Frequently Asked Questions about Cresset
Cresset was founded in 2002 and raised its 1st funding round 9 years after it was founded.
Cresset is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Robert Scoffin is the current CEO of Cresset.
Cresset is a funded company, having raised a total of $297.86K across 8 funding rounds to date.
As of Mar 31, 2022, the latest employee count at Cresset is 46.
Founded in 2002 and headquartered in Cambridge, United Kingdom, Cresset operates in the computational chemistry sector. Software solutions are offered that employ algorithms emphasizing ligand biological activity over chemical similarity to forecast structure-activity relationships. Five suites are available: Torch for molecular design, Spark for moiety replacements, Forge for SAR exploration, Blaze for library screening, and XedTools with XED force field integration. Drug discovery services are additionally provided.
Cresset offers Flare, Spark, Blaze, and Torx DMTA.
Cresset has 3 investors. Key investors include Gov.uk, European Union, and Scottish Equity Partners.
The valuation of Cresset is $905.52K as of Sep 2022.